QuidelOrtho Reports Strong Q1 2025 Financial Results

Quidelortho Corporation ( (QDEL) ) has released its Q1 earnings. Here is a breakdown of the information Quidelortho Corporation presented to its investors.

QuidelOrtho Corporation is a leading provider of in-vitro diagnostic technologies, specializing in point-of-care settings, clinical labs, and transfusion medicine, offering innovative solutions in the healthcare sector.

In its first quarter of 2025, QuidelOrtho reported a total revenue of $693 million, reflecting a 5% growth as reported and 6% in constant currency, excluding COVID-19 and Donor Screening revenues. The company highlighted strong execution on cost-saving initiatives, which contributed to improved margins and profitability.

Key financial metrics revealed a significant improvement in operating income, which reached $33 million, compared to a substantial operating loss in the previous year. The adjusted EBITDA margin increased to 23%, up by 450 basis points, driven by cost-saving measures. The Labs business showed a 5% revenue growth, while Donor Screening revenue saw a decline as the company winds down this segment in the U.S.

Despite a decrease in total revenue due to lower COVID-19 and Donor Screening revenues, the company maintained its full-year 2025 financial guidance. Adjusted diluted earnings per share rose to $0.74, compared to $0.44 in the prior year, indicating a positive trajectory in earnings.

Looking ahead, QuidelOrtho remains committed to commercial excellence and margin expansion, with management maintaining a positive outlook for the remainder of 2025, focusing on supporting customers and patients who rely on their diagnostic products.